Cell Enriched Autologous Fat Grafts to Follicular Niche Improves Hair Regrowth in Early Androgenetic Alopecia

Abstract

Background Adipose and adipose derived regenerative cells (ADRCs) play an increasing role in androgenetic alopecia. Objectives The authors sought to evaluate the safety and feasibility of fat grafts enriched with ADRCs in early androgenetic alopecia. Methods Seventy-one patients were treated: 16 with Puregraft fat and 1.0 × 106 ADRCs/cm2 scalp; 22 with Puregraft fat and 0.5 × 106 ADRCs/cm2 scalp, 24 with Puregraft fat alone, and 9 with saline control. Treatments were delivered into the skin and subcutaneous layer of the scalp. A total of 40 cm2 of scalp was treated and macrophotography and global photography were obtained at baseline and at 6, 24, and 52 weeks. Results A total of 71 patients tolerated the procedures well. No unanticipated associated adverse events were reported. When evaluating all patients at 24 weeks, there were no statistical differences between any of the treatment groups with respect to nonvellus (terminal) hair counts or width. There were increases (mean change from baseline) in terminal hair count for the low-dose ADRC group in the Norwood Hamilton 3 subgroup at week 6 (13.90 ± 16.68), week 12 (11.75 ± 19.42), week 24 (16.56 ± 14.68), and week 52 (2.78 ± 16.15). For this subgroup, the difference in hair count between the low-dose ADRC group and no-fat saline control was statistically significant (P = 0.0318) at week 24. Conclusions Puregraft fat and ADRCs are safe and well tolerated. In early male hair loss, this therapy demonstrated a statistically significant increase in terminal hair counts relative to the control population at 24 weeks and represents a promising approach for early androgenetic alopecia. Level of Evidence: 2

Hair Transplantation in Cicatricial Alopecia: The Role of Autologous Fat Transfer

“…Among them is worth mentioning the PAHT (peripheral areas HT), a recent proposal by Dr. Sebastián Yriart to extend the harvesting area to the regions surrounding the scar considering the AGA evolution scenario [22]. Even considering all these new strategies, the necessity to improve the trophism of the receiving tissue prior to perform HT to overcome the reliability of the results remains the same [23].…”

Different Levels of EGF, VEGF, IL-6, MCP-1, MCP-3, IP-10, Eotaxin and MIP-1𝛼 in Adipose Derived Stem Cells (ADSCs) Secretome in Androgenetic Alopecia

“…This may be, besides rapid cell death upon transplantation, another explanation of the modest bene t of MSC transplantation observed in alopecia clinical trials. [28,29] There is a far greater potential behind the regenerative treatments that has not been explored for AGA. The use of the ADSCs secretome as a therapeutic agent in AGA could be a promising new avenue.…”

Comparative technical analysis of lipoaspirate mechanical processing devices

“…In one work (Brzezienski & Jarrell, 2016), surgeons indifferently used the GID700 and Puregraft devices, and no comparison of clinical results is made. The identified clinical results refer to multiple fields of application: 14 papers refer to breast reconstruction (Brzezienski & Jarrell, 2016;Chiu, Fracol, Feld, Qiu, & Kim, 2019;De Fazio & Cingozoglu, 2020;Economides & Song, 2018;Gabriel et al, 2017;Lee et al, 2011;Losken et al, 2011;Mestak et al, 2014;Mestak, Mestak, Bohac, Edriss, & Sukop, 2013;Mestak & Zimovjanová, 2012;Ruan et al, 2019;Russe et al, 2015;Sforza, Andjelkov, Zaccheddu, Husein, & Atkinson, 2016;Wang et al, 2012), 5 to osteoarthritis (4 of the knee and 1 of the hip) (Barfod & Blønd, 2019;Dall'Oca et al, 2019;Jones et al, 2018;Panchal, Malanga, & Sheinkop, 2018;Schiavone Panni et al, 2019), 3 to complex anal fistula (Laureti et al, 2020;Naldini, Sturiale, Fabiani, Giani, & Menconi, 2018;Topal, Eray, Rencüzo gulları, Yalav, & Alabaz, 2019), whereas 8 studies concern different pathologies (Casarotti, Chiodera, & Tremolada, 2018;Cestaro, De Rosa, Massa, Amato, & Gentile, 2015;Cherian, Malanga, Hogaboom, Pollack, & Dyson-Hudson, 2019;Hirahara, Andersen, & Panero, 2017;Kuka et al, 2020;Lonardi et al, 2019;Saibene, Pipolo, Lorusso, Portaleone, & Felisati, 2015;Zuin et al, 2019). The interesting fact is that all the aforementioned devices are mainly used for breast reconstructions, exc...…”